Ann: Preliminary Top-line Results from SMARTCOUGH-C Study, page-181

Tbh, after reading the announcement again, it is very clear that RAP ought to consider strongly a clinical research PhD (ie a medical practitioner, preferably an experienced paediatrician or respiratory physician, with a clinical research PhD) with an appropriate skillset to lead their involvement in a second trial and do a dummy run perhaps, or more than one, to iron out potentially catastrophic variables.

Apologies if this was already done.